Review
Biochemistry & Molecular Biology
Alisan Kayabolen, Ebru Yilmaz, Tugba Bagci-Onder
Summary: The discovery of mutations in IDH genes in gliomas a decade ago has challenged our understanding of the role of metabolism in tumor progression. These mutations are common in lower grade gliomas and secondary glioblastomas, driving tumorigenesis. Inhibiting mutant IDH enzymes is seen as a promising therapeutic strategy, while exploiting the vulnerabilities caused by these mutations may offer another attractive approach.
Article
Immunology
Saadia Ait Ssi, Dounia Chraa, Khadija El Azhary, Souha Sahraoui, Daniel Olive, Abdallah Badou
Summary: Our study revealed two distinct patient groups in glioma based on the presence of different immune cells, one associated with better survival and the other with poor survival. This highlights the potential mechanisms behind therapy failure and the tight implication of immune components on glioma patient prognosis, offering insights for developing better immune-based therapeutic approaches.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Clinical Neurology
Ruham Alshiekh Nasany, Macarena Ines de la Fuente
Summary: This article provides a review of the unique characteristics, behavior, and disease outcomes of IDH mutant gliomas, as well as the standard of care treatment options and innovative therapeutic approaches currently being investigated.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2023)
Article
Oncology
Ningfang Du, Xiaotao Zhou, Renling Mao, Weiquan Shu, Li Xiao, Yao Ye, Xinxin Xu, Yilang Shen, Guangwu Lin, Xuhao Fang, Shihong Li
Summary: This study explored the correlation between MRI morphological characteristics, apparent diffusion coefficient (ADC) parameters, and pathological grades as well as IDH gene phenotypes of gliomas. Multivariable logistic regression models combining MRI features and ADC parameters were developed to predict glioma grades and IDH mutation status, providing a noninvasive and preoperative approach.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Marina Radoul, Donghyun Hong, Anne Marie Gillespie, Chloe Najac, Pavithra Viswanath, Russell O. Pieper, Joseph F. Costello, Hema Artee Luchman, Sabrina M. Ronen
Summary: This study used H-1-MRS to identify early metabolic biomarkers of response to mutant IDH inhibition, showing significant increase in GLX and glutamate, as well as transient elevation of NAA after treatment with AG-881 and BAY-1436032. Improved animal survival and metabolic changes were observed prior to detectable differences in tumor volume between control and treated groups.
Article
Oncology
Yanhao Liu, Peng Wang, Shaoyu Wang, Huapeng Zhang, Yang Song, Xu Yan, Yang Gao
Summary: This study explained the heterogeneity of adult-type diffuse gliomas through diffusion kurtosis imaging-based habitat characteristics and developed and validated a comprehensive model for predicting isocitrate dehydrogenase (IDH) status. The model showed high diagnostic performance and robustness compared to single-modality models.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Michael Naidoo, Leanne Jones, Benjamin Conboy, Wael Hamarneh, Darwin D'Souza, Karen Anthony, Lee R. Machado
Summary: The expression of the DMD gene is associated with the survival outcomes of low-grade glioma (LGG). High DMD expression is significantly associated with poor survival, especially in IDH mutant cases, which suggests its potential as an independent prognostic marker for LGG.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Hang Cao, E. Zeynep Erson-Omay, Murat Gunel, Jennifer Moliterno, Robert K. Fulbright
Summary: The study found that report length varied depending on age, glioma grade, and IDH status, with diverse descriptions of glioma enhancement patterns. Report features were able to predict glioma IDH status effectively.
FRONTIERS IN ONCOLOGY
(2021)
Review
Clinical Neurology
Julie J. Miller
Summary: Standard treatment for IDH-mutant gliomas is non-curative and associated with long-term neurotoxicity. Various targeted therapeutic strategies, including direct IDH inhibitors and strategies taking advantage of IDH-mutant-specific vulnerabilities, are in development.
Editorial Material
Medicine, General & Internal
Elizabeth B. Claus, Roel G. W. Verhaak
Summary: The editorial discusses the use of vorasidenib, an inhibitor of variant isocitrate dehydrogenase, in the treatment of grade 2 glioma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Health Care Sciences & Services
Luca Pasquini, Antonio Napolitano, Emanuela Tagliente, Francesco Dellepiane, Martina Lucignani, Antonello Vidiri, Giulio Ranazzi, Antonella Stoppacciaro, Giulia Moltoni, Matteo Nicolai, Andrea Romano, Alberto Di Napoli, Alessandro Bozzao
Summary: A specialized deep-learning model tailored for GBM was developed to predict IDH mutations using convolution neural networks on multiparametric MRI. The model demonstrated varying levels of accuracy and loss values in the test cohort, with the highest predictivity achieved on perfusion images.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Soufyan Annakib, Valerie Rigau, Amelie Darlix, Catherine Goze, Hugues Duffau, Luc Bauchet, Marta Jarlier, Michel Fabbro
Summary: This study retrospectively evaluated the clinical outcomes of bevacizumab as rescue treatment for recurrent WHO grades II-III glioma, and found that bevacizumab displayed prolonged activity in a subset of patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Julie J. Miller, Alexandria Fink, Jack A. Banagis, Hiroaki Nagashima, Megha Subramanian, Christine K. Lee, Lisa Melamed, Shilpa S. Tummala, Kensuke Tateishi, Hiroaki Wakimoto, Daniel P. Cahill
Summary: Activation of Sirt1 can selectively target IDH-mutant tumors by reducing NAD+ levels and inhibiting cell growth, especially when combined with NAMPT inhibitors to enhance cytotoxicity.
Editorial Material
Hematology
Andrew H. Wei, Naval Daver
Summary: This study demonstrates the feasibility of combining IDH inhibitors with intensive induction and consolidation therapy, laying the foundation for further exploration of targeted IDH therapy as standard treatment for newly diagnosed IDH-mutant AML patients.
Article
Chemistry, Multidisciplinary
Tao Wang, Yunxia Zhou, Yunping Fan, Hao Duan, Xiaoyu Guo, Jinlong Chang, Youheng Jiang, Changxue Li, Zhang Fu, Yunfei Gao, Xiaoran Guo, Kastytis Sidlauskas, Zhenqiang He, Clive Da Costa, Xia Sheng, Dinglan Wu, Jinqiu Yuan, Huiliang Li, Yulong He, Yonggao Mou, Ningning Li
Summary: This study demonstrates that IDH mutation induces metabolic reprogramming in gliomas and influences the phenotypes of glioma-associated microglia/macrophages (GAMs). Gliomas expressing mutant IDH promote M1-like polarization of GAMs, while typical IDH induces M2-like polarization. Furthermore, the study reveals the involvement of the PERK/miR-19a/LDLR signaling pathway in regulating gliomal cholesterol transport and GAM phenotypes, suggesting it as a potential target pathway for glioma therapy.
Article
Oncology
Tao Jiang, Ying Mao, Wenbin Ma, Qing Mao, Yongping You, Xuejun Yang, Chuanlu Jiang, Chunsheng Kang, Xuejun Li, Ling Chen, Xiaoguang Qiu, Weimin Wang, Wenbin Li, Yu Yao, Shaowu Li, Shouwei Li, Anhua Wu, Ke Sai, Hongmin Bai, Guilin Li, Baoshi Chen, Kun Yao, Xinting Wei, Xianzhi Liu, Zhiwen Zhang, Yiwu Dai, Shengqing Lv, Liang Wang, Zhixiong Lin, Jun Dong, Guozheng Xu, Xiaodong Ma, Jinquan Cai, Wei Zhang, Hongjun Wang, Lingchao Chen, Chuanbao Zhang, Pei Yang, Wei Yan, Zhixiong Liu, Huimin Hu, Jing Chen, Yuqing Liu, Yuan Yang, Zheng Wang, Zhiliang Wang, Yongzhi Wang, Gan You, Lei Han, Zhaoshi Bao, Yanwei Liu, Yinyan Wang, Xing Fan, Shuai Liu, Xing Liu, Yu Wang, Qixue Wang
Article
Oncology
Pei Yang, Jinquan Cai, Wei Yan, Wei Zhang, Yinyan Wang, Baoshi Chen, Guilin Li, Shouwei Li, Chenxing Wu, Kun Yao, Wenbin Li, Xiaoxia Peng, Yongping You, Ling Chen, Chuanlu Jiang, Xiaoguang Qiu, Tao Jiang
Article
Oncology
Zengjin Liu, Huamin Han, Xin He, Shouwei Li, Chenxing Wu, Chunjiang Yu, Shengdian Wang
Article
Oncology
Pei Yang, Chuanbao Zhang, Jinquan Cai, Gan You, Yinyan Wang, Xiaoguang Qiu, Shouwei Li, Chenxing Wu, Kun Yao, Wenbin Li, Xiaoxia Peng, Wei Zhang, Tao Jiang
Article
Oncology
Peng-Fei Wang, Hong-Wang Song, Hong-Qing Cai, Ling-Wei Kong, Kun Yao, Tao Jiang, Shou-Wei Li, Chang-Xiang Yan
Article
Multidisciplinary Sciences
Peng-fei Wang, Wen-Jun Ji, Xiao-hui Zhang, Shou-wei Li, Chang-Xiang Yan
SCIENTIFIC REPORTS
(2017)
Article
Pharmacology & Pharmacy
Peng-Fei Wang, Yang Chen, Si-Ying Song, Ting-Jian Wang, Wen-Jun Ji, Shou-Wei Li, Ning Liu, Chang-Xiang Yan
FRONTIERS IN PHARMACOLOGY
(2017)
Article
Pathology
Hong-Qing Cai, Peng-Fei Wang, Hai-Peng Zhang, Zhi-Jian Cheng, Shou-Wei Li, Jie He, Yu Zhang, Jia-Jie Hao, Ming-Rong Wang, Chang-Xiang Yan, Jing-Hai Wan
JOURNAL OF CLINICAL PATHOLOGY
(2018)
Article
Immunology
Peng-fei Wang, Hong-qing Cai, Chuan-bao Zhang, Yan-Michael Li, Xiang Liu, Jing-hai Wan, Tao Jiang, Shou-wei Li, Chang-xiang Yan
JOURNAL OF NEUROINFLAMMATION
(2018)
Article
Oncology
Peng-Fei Wang, Zhe Meng, Hong-Wang Song, Kun Yao, Ze-Jun Duan, Shou-Wei Li, Chang-Xiang Yan
Review
Oncology
Peng-Fei Wang, Si-Ying Song, Ting-Jian Wang, Wen-Jun Ji, Shou-Wei Li, Ning Liu, Chang-Xiang Yan
Article
Multidisciplinary Sciences
Ling-Wei Kong, Jin Chen, Heng Zhao, Kun Yao, Sheng-Yu Fang, Zheng Wang, Yin-Yan Wang, Shou-Wei Li
SCIENTIFIC REPORTS
(2019)
Article
Cell Biology
Chao Yang, Yanli Tan, Shouwei Li, Junhu Zhou, Qixue Wang, Yunfei Wang, Yingbin Xie, Luyue Chen, Jie Li, Chuan Fang, Chunsheng Kang
Article
Oncology
Peng-fei Wang, Jianbin Zhang, Hong-qing Cai, Zhe Meng, Chun-jiang Yu, Shou-wei Li, Jing-hai Wan, Chang-Xiang Yan